FZD9 and ovarian carcinoma: For example, SPRY4 affects cell growth as a downstream effector of Wnt7A/Fzd9 signaling in ovarian cancer (Chen et al., 2017), breast cancer (Tian et al., 2018), colorectal cancer (Bienz and Clevers, 2000) and prostate cancer (Bisson and Prowse, 2009).